SGHTSight Sciences Inc. Common Stock

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index rising 3.1% a

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index rising 2.2% and th

Dry eye adoption scaled while glaucoma gained major insurance coverage.

Sight Sciences Inc (SGHT) delivers its strongest quarterly growth in three years, driven by record dry eye revenue and improved operational efficiency.

Sight Sciences (NASDAQ:SGHT) reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjus

The fair value estimate for Sight Sciences has shifted from US$9.35 to US$8.40, pointing to a more measured central valuation in the latest update. This adjustment lines up with recent Street research, where some analysts have trimmed targets and leaned on more cautious assumptions even as interest in the eyecare sector remains. In the following sections, you will see how these changing views, and the updated guidance, shape the evolving Sight Sciences narrative and what that might mean for...

Sight Sciences (SGHT) delivered earnings and revenue surprises of +46.67% and +7.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Integra (IART) delivered earnings and revenue surprises of +16.67% and -0.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?